Angiodynamic Inc (ANGO) concluded trading on Thursday at a closing price of $6.37, with 2.24 million shares of worth about $14.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -0.47% during that period and on October 03, 2024 the price saw a loss of about -16.73%. Currently the company’s common shares owned by public are about 40.43M shares, out of which, 38.24M shares are available for trading.
Stock saw a price change of -15.18% in past 5 days and over the past one month there was a price change of -13.10%. Year-to-date (YTD), ANGO shares are showing a performance of -18.75% which decreased to -16.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.26 but also hit the highest price of $8.25 during that period. The average intraday trading volume for Angiodynamic Inc shares is 495.21K. The stock is currently trading -15.32% below its 20-day simple moving average (SMA20), while that difference is down -15.38% for SMA50 and it goes to -2.47% lower than SMA200.
Angiodynamic Inc (NASDAQ: ANGO) currently have 40.43M outstanding shares and institutions hold larger chunk of about 79.52% of that.
The stock has a current market capitalization of $258.81M and its 3Y-monthly beta is at 0.66. It has posted earnings per share of -$6.04 in the same period. It has Quick Ratio of 1.41 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ANGO, volatility over the week remained 6.06% while standing at 3.88% over the month.
Stock’s fiscal year EPS is expected to drop by -7.02% while it is estimated to increase by 71.72% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on April 05, 2024 offering an Outperform rating for the stock and assigned a target price of $12 to it. Coverage by H.C. Wainwright stated Angiodynamic Inc (ANGO) stock as a Buy in their note to investors on September 25, 2023, suggesting a price target of $19 for the stock. On April 17, 2023, Raymond James Downgrade their recommendations, while on October 15, 2021, Canaccord Genuity Upgrade their ratings for the stock with a price target of $37. Stock get a Perform rating from Oppenheimer on August 20, 2021.
